| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | sotorasib (Lumykras®) |
| Formulation | 120 mg film-coated tablet |
| Reference number | 4839 |
| Indication | Monotherapy for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/01/2022 |
| NICE guidance | |